Jason Beaubien

Jason Beaubien is NPR's Global Health and Development Correspondent on the Science Desk.

In this role, he reports on a range of issues across the world. He's covered the plight of Rohingya refugees in Bangladesh, mass cataract surgeries in Ethiopia, abortion in El Salvador, poisonous gold mines in Nigeria, drug-resistant malaria in Myanmar and tuberculosis in Tajikistan. He was part of a team of reporters at NPR that won a Peabody Award in 2015 for their extensive coverage of the West Africa Ebola outbreak. His current beat also examines development issues including why Niger has the highest birth rate in the world, can private schools serve some of the poorest kids on the planet and the links between obesity and economic growth.

Prior to becoming the Global Health and Development Correspondent in 2012, Beaubien spent four years based in Mexico City covering Mexico, Central America and the Caribbean. In that role, Beaubien filed stories on politics in Cuba, the 2010 Haitian earthquake, the FMLN victory in El Salvador, the world's richest man and Mexico's brutal drug war.

For his first multi-part series as the Mexico City correspondent, Beaubien drove the length of the U.S./Mexico border making a point to touch his toes in both oceans. The stories chronicled the economic, social and political changes along the violent frontier.

In 2002, Beaubien joined NPR after volunteering to cover a coup attempt in the Ivory Coast. Over the next four years, Beaubien worked as a foreign correspondent in sub-Saharan Africa, visiting 27 countries on the continent. His reporting ranged from poverty on the world's poorest continent, the HIV in the epicenter of the epidemic, and the all-night a cappella contests in South Africa, to Afro-pop stars in Nigeria and a trial of white mercenaries in Equatorial Guinea.

During this time, he covered the famines and wars of Africa, as well as inspiring preachers and Nobel laureates. Beaubien was one of the first journalists to report on the huge exodus of people out of Sudan's Darfur region into Chad, as villagers fled some of the initial attacks by the Janjawid. He reported extensively on the steady deterioration of Zimbabwe and still has a collection of worthless Zimbabwean currency.

In 2006, Beaubien was awarded a Knight-Wallace fellowship at the University of Michigan to study the relationship between the developed and the developing world.

Beaubien grew up in Maine, started his radio career as an intern at NPR Member Station KQED in San Francisco and worked at WBUR in Boston before joining NPR.

In some countries, citizens are grumbling about the inefficient rollout of COVID-19 vaccines. It's unclear exactly when doses will be available. Websites for appointments keep crashing. Lines are long.

And then there are the 130 countries that "are yet to administer a single dose," according to UNICEF. That's 2.5 billion people who so far have been completely shut out of the global vaccine campaign.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

MARY LOUISE KELLY, HOST:

Peru is scrambling to get access to COVID vaccines as cases spike.

But the Latin American nation is in a tough slot.

The first problem is its relative wealth. Peru is classified by the World Bank as "upper middle-income." So it has some money to spend on vaccines but not nearly the financial resources of the U.S., the European Union or even wealthier neighbors like Brazil or Chile. But it's not poor enough to qualify for free doses from COVAX, the global program aimed at assuring equitable access to vaccines.

The New York Mets have fired the team's new general manager Jared Porter over alleged sexual harassment of a female reporter.

Guatemala security forces are attempting to block thousands of Honduran migrants from heading north towards Mexico and the U.S. border.

On Sunday, police and soldiers in riot gear confronted a caravan of migrants from Honduras on a highway near Chiquimula in southeastern Guatemala. After a tense standoff, in which police fired tear gas and attempted to beat back the migrants with batons, the surging crowd broke through a phalanx of soldiers.

As nations around the world scramble to start vaccinating against COVID-19, many countries are finding it difficult if not impossible to get the vaccines they want.

Case in point — Argentina. President Alberto Fernández promised to start vaccination campaigns in the South American nation before the end of 2020.

Even disaster experts are stunned by the devastation this fall in Honduras.

"I've been to too many disasters all over the world," says Vlatko Uzevski, who arrived in Honduras last week from Macedonia to lead an emergency response team for Project Hope.

"And I have never been to a place that was struck by two hurricanes in two weeks," says Uzevski, a physician who has been doing this type of work for 15 years.

Coronary heart disease and stroke are the two leading causes of death for Homo sapiens on planet Earth, according to a new report from the World Health Organization. This fact has remained unchanged for the past two decades. But this analysis of global deaths over the past 20 years finds significant shifts in how people die — as well as dramatic differences in what leads to death in different regions.

Noncommunicable diseases such as dementia and diabetes are now claiming more lives, while infectious diseases such as HIV and tuberculosis are taking far fewer.

A once-promising treatment against COVID-19 has fallen out of favor with the World Health Organization.

On Thursday, a WHO review panel issued new guidelines recommending against the use of remdesivir for COVID-19 — even though the medicine is one of the few to win regulatory approval as a treatment for the disease.

Steven used to take a pill every morning to control his HIV. Then he heard about a study for a ground-breaking treatment where he wouldn't have to take any pills at all.

"I get an injection in each butt cheek once a month," says Steven, an attorney based in Pittsburgh, Pa., who tested positive in 2015.

He's asked us to withhold his last name because while he came out as gay last year, he hasn't come out to all his professional contacts.

The drug he's getting is called Cabenuva. It's one of a new type of anti-AIDS drugs that need to be taken only a few times a year.

Pages